JP2008297222A - Composition for ameliorating accommodative dysfunction of eye - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a food composition and a pharmaceutical composition effective for ameliorating accommodative dysfunction of eye and asthenopia of person feeling the accommodative dysfunction or asthenopia. <P>SOLUTION: The invention provides a food composition and a pharmaceutical composition compounded with both of a xanthophyll which is a pigment mass-produced by natural organisms (especially astaxanthin) and an extract containing a peptide derived from a lean fish (especially fish of the suborder Scombroidei) as active components. The composition exhibits remarkable effect for ameliorating accommodative dysfunction of eye and asthenopia. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  TECHNICAL FIELD The present invention relates to a composition having an effect of improving ocular dysfunction by using xanthophylls and peptides as active ingredients. More specifically, the present invention relates to a composition having an effect of improving ocular regulatory dysfunction, comprising a hematococcus alga extract containing astaxanthin and a red fish extract containing a peptide as active ingredients. The present invention also relates to pharmaceuticals, foods, and functional foods containing the ophthalmic regulatory dysfunction composition.

  The eye has a function that automatically adjusts the focal point on the retina by making the lens thicker when looking close and thinning the lens when looking far away. This disorder of regulation includes presbyopia in which the ability to adjust decreases with age and makes near vision difficult, and in pathological abnormalities, adjustment weakness, dysregulation, retardation, adjustment paralysis, adjustment tension, and adjustment convulsions Etc. In particular, the causes of the latter pathological abnormalities include fatigue of the eye ciliary body, fatigue of the eye muscles that move the eyeballs, fatigue of the optic nerve, systemic diseases, and other eye diseases. It is said that there is no cure for presbyopia, and the symptomatically reduced accommodation is supplemented with glasses or contact lenses. For pathological abnormalities, the cause disease is treated and the environment is improved. As symptomatic therapy, glasses and vitamin B are used.

  There are only a few therapies for ocular regulatory dysfunction, and there are currently few preventive treatments. The present applicant has clarified that astaxanthin has an effect of improving the eye regulation function (Patent Document 1). It is known that the bonito extract has an effect of recovering eye fatigue (Patent Document 2) and that the eye fatigue is improved by continuously ingesting bonito soup stock (Non-Patent Document 1). . However, it is not known that a composition containing xanthophyll and a peptide has a higher effect of improving ocular regulatory dysfunction.

Japanese Special Reissue WO 2002/094253 International Publication WO2005 / 087022 Pamphlet Visual Science, 27, 95-101, 2006

  As a result of searching for substances for improving ocular regulatory dysfunction, the present inventors have found that a composition containing xanthophyll and a peptide has an excellent effect of improving ocular regulatory dysfunction. The present invention has been completed based on such findings, and provides an ophthalmic regulatory dysfunction composition containing xanthophyll and a peptide as active ingredients, and a pharmaceutical, food and drink containing the ophthalmic regulatory dysfunction composition. Is.

  As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that a composition containing xanthophyll and peptide has a marked improvement in ocular regulatory dysfunction. The present invention is based on such knowledge.

  By taking the composition for improving eye accommodation dysfunction according to the present invention in the form of pharmaceuticals, foods, etc., improvement and prevention of eye accommodation dysfunction and improvement of eye strain caused by eye accommodation dysfunction are also improved. be able to.

  In the present invention, xanthophylls are astaxanthin, zeaxanthin, lutein, cryptoxanthine, tunaxanthin, salmoxanthine, parasiloxanetin, violaxanthin, anthaxanthin, cucurbitaxanthin, diatoxanthine, alloxanthin, pectinol, pectinolone, and mactra. Xanthine, capsanthin, capsanthinol, fucoxanthin, fucoxanthinol, peridinin, halocinthiaxanthine, amarosiaxanthine, canthaxanthin, echinone, rhodoxanthine, bixin, norbixin, preferably astaxanthin, cryptoxanthin, zeaxanthin , Lutein, canthaxanthin, capsanthin, fucoxanthin, particularly preferably astaxanthin That. As these xanthophylls, those extracted from natural products such as plants, animals, microorganisms, and chemically synthesized products can be used. Extracts of substances from natural products are not particularly limited in terms of raw material type, production area and production method.

  In the description of the present invention, xanthophyll includes xanthophyll and / or its ester unless otherwise specified. Furthermore, the ester of xanthophyll includes a monoester form and / or a diester form.

  As the xanthophyll of the present invention, at least one of xanthophyll free form, monoester form and diester form can be used. Diesters are chemically and physically more stable than free and monoesters because two hydroxyl groups are protected by ester bonds, and are less susceptible to oxidative degradation in the composition of the present invention. However, it is considered that when it is taken up by an enzyme in the intestine or into the living body, it is rapidly hydrolyzed to xanthophyll by the in vivo enzyme and exhibits an effect.

  Examples of the monoester of xanthophyll include esters esterified with lower or higher saturated fatty acids or lower or higher unsaturated fatty acids. Specific examples of the lower or higher saturated fatty acid or the lower or higher unsaturated fatty acid include acetic acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, palmitooleic acid, hebutadecanoic acid, elaidic acid, ricinoleic acid, and betrothelin. Acid, vaccenic acid, eleostearic acid, punicic acid, ricinic acid, parinaric acid, gadoric acid, 5-eicosenoic acid, 5-docosenoic acid, cetoleic acid, erucic acid, 5,13-docosadienoic acid, ceracholic acid, decenoic acid , Stering acid, dodecenoic acid, oleic acid, stearic acid, eicosaopentaenoic acid, docosahexaenoic acid, linoleic acid, linolenic acid, arachidonic acid and the like. Examples of carotenoid diesters include diesters esterified with the same or different fatty acids selected from the group consisting of the above fatty acids.

  Furthermore, xanthophyll monoesters include amino acids such as glycine and alanine; monovalent or polyvalent carboxylic acids such as acetic acid and citric acid; inorganic acids such as phosphoric acid and sulfuric acid; sugars such as glucoside; glycerosugar fatty acids and sphingosaccharides. Examples thereof include sugar esters such as fatty acids; fatty acids such as glycero fatty acids; monoesters esterified with glycerophosphoric acid and the like. In addition, the salt of the said monoester is also included when it can be considered. Examples of fatty acid derivatives include phospholipid type, alcohol type, ether type, sucrose ester type and polyglycerin ester type of the above fatty acids.

  As the diester of xanthophyll, the group consisting of the lower saturated fatty acid, higher saturated fatty acid, lower unsaturated fatty acid, higher unsaturated fatty acid, amino acid, monovalent or polyvalent carboxylic acid, inorganic acid, sugar, sugar fatty acid, fatty acid and glycerophosphoric acid And diesters esterified with the same or different acids selected from In addition, the salt of the said diester is also included when it can be considered. Examples of the diester of glycerophosphoric acid include saturated fatty acid esters of glycerophosphoric acid or glycerophosphoric acid esters containing fatty acids selected from higher unsaturated fatty acids, unsaturated fatty acids or saturated fatty acids.

  Astaxanthin means a product derived from a natural product or obtained by synthesis. Examples of those derived from natural products include microalgae such as Haematococcus algae, yeasts such as red yeast Phaffia, crustacean shells such as shrimp, krill and crabs, craniopod viscera such as squid and octopus, various Adonis genus petals such as seafood skins and fins of seafood, alpha-proteobacteria such as Paracoccus sp. N81106, Brevundimonas sp. SD212, Erythrobacter sp. PC6, and Gordonia sp. KANMONKAZ-1129 Examples thereof include those obtained from fungi, Labyrinthulas such as Schizophytriuym sp. KH105 (especially Yabetaceae) and astaxanthin-producing genetically modified organisms. Natural extracts and chemically synthesized products are commercially available and are readily available.

  Astaxanthin is 3,3′-dihydroxy-β, β-carotene-4,4′-dione and has stereoisomers. Specifically, three stereoisomers of (3R, 3′R) -astaxanthin, (3R, 3 ′S) -astaxanthin and (3S, 3 ′S) -astaxanthin are known. Any of these can be used. The present invention includes monoesters and diesters of these astaxanthin isomers.

  In the present invention, as the fatty acid ester of astaxanthin, any of those derived from natural products or those obtained by synthesis can be used, but those derived from natural products in which the astaxanthin ester is dissolved in various oils and fats are preferred from absorption in the body. Natural sources include, for example, a krill extract, a faffia yeast extract, and a hematococcus alga extract. Particularly preferred is a hematococcus alga extract depending on the stability of astaxanthin and the type of ester of astaxanthin.

  Fatty acid esters of astaxanthin have not been observed to be mutagenic, are known to be highly safe compounds, and are widely used as food additives (Jiro Takahashi et al .: Toxicity test of hematococcus alga astaxanthin-Ames Test, rat single dose toxicity test, rat 90 day repeated oral dose toxicity test-, clinical medicine, 20: 867-881, 2004).

  Haematococcus algae is a green algae belonging to the Volboxic Chlamydomonas family, and since it is a green algae, it has a high chlorophyll content and is green, and it swims in the water with two flagella, but it lacks nutrient sources, changes in temperature, etc. Under starvation conditions, dormant spores are formed, the astaxanthin content is increased, and red spheres are formed. In the present invention, Haematococcus algae in any state can be used, but it is preferable to use Haematococcus algae that have become dormant spores containing a large amount of astaxanthin. In addition, among green algae belonging to the genus Haematococcus, for example, Haematococcus pluvialis is preferable.

  As a method for culturing Haematococcus green algae, a hermetically sealed culture method is preferred in which no foreign microorganisms are mixed and propagated and other contaminants are not mixed. For example, a partially open dome shape, conical shape or cylindrical shape is preferable. A culture method using a culture medium having a culture apparatus and a gas discharge device movable within the apparatus (International Publication No. 99/50384), or culturing by irradiating light from inside a sealed culture apparatus And a method using a flat culture tank or a tube-type culture layer are suitable.

  The method for obtaining an extract from Haematococcus algae according to the present invention includes a method in which Haematococcus algae is dried and pulverized and then extracted with an organic solvent such as acetone or alcohol, and the Haematococcus algae is suspended in an organic solvent and pulverized and extracted simultaneously. Or a supercritical extraction method using carbon dioxide or the like.

  The supercritical extraction method can be performed by a conventional method. For example, Hirose (Ind Eng Chem Res, 2006, 45 (10), 3652-3657, Extraction of Astaxanthin from Haematococcus pluvialis Using Supercritical CO2 and Ethanol as Entrainer) Can be done by the method.

  Various methods are known for extraction and purification from the culture or the crustacean using an organic solvent. For example, since astaxanthin and its esters are oil-soluble substances, astaxanthin-containing components can be extracted from natural products containing astaxanthin with an oil-soluble organic solvent such as acetone, alcohol, ethyl acetate, benzene, and chloroform. Also, supercritical extraction can be performed using carbon dioxide, water, or the like. After extraction, the solvent is removed according to a conventional method to obtain a mixed concentrate of monoester type astaxanthin and diester type astaxanthin. The obtained concentrate can be further purified by separation column or lipase decomposition, if desired.

  A method of drying Haematococcus algae cultured in the above-mentioned dome type culture apparatus or closed type culture apparatus, extracting with acetone after pulverization, or performing pulverization and extraction in acetone at the same time, and then removing acetone to extract astaxanthin However, as a result of purifying after purifying by supercritical extraction, there is almost no oxidation of astaxanthin because there is no contact with air, there are few impurities, that is, there are few substances that inhibit the effect of the present invention, and astaxanthin and triglyceride are contained. It can be contained in a large amount with good purity and is suitable.

  In the present invention, a peptide is a peptide obtained from a natural animal or plant and has an anti-fatigue effect, and is a red fish, particularly a fish having a lot of myoglobin pigments, such as horse mackerel, sardine, anchovy, skipjack, amberjack It is a peptide contained in an extract extracted from the lean part of migratory fish such as mackerel, mackerel, saury, striped sea bream, herring, yellowtail, tuna and mulo horse mackerel. In the present invention, it can be used as an extract containing these peptides. The red fish extract used in the present invention is not particularly limited in its production method, and can be obtained by a conventional method. As long as the composition is the same, an extract produced by a different production method may be used.

  As a method for extracting red fish used in the present invention, for example, meat broth and / or steamed soup of bonito, tuna, mackerel, sardine, etc. are concentrated by about 20 to 40 times by a conventional method and then filtered. It is treated with an enzyme such as protease at 20 to 60 ° C. for 1 minute to 24 hours and concentrated about 40 to 60 times. After adding saccharides (for example, glucose, fructose, etc.) to this extract in the range of 0.1 to 10%, browning treatment is performed at 60 to 150 ° C. for 1 minute to 24 hours to form powder. be able to. In addition, after migrating the internal organs, body and head of the migratory fish described above, they may be fermented, filtered, and filtered (Japanese Patent Laid-Open No. 2002-191321). Furthermore, the above-mentioned migratory fish meat broth and / or steamed broth can be heated and concentrated about 20-50 times by a conventional method and then filtered.

  When the composition for improving eye accommodation function of the present invention is used, it can be used in the form of ordinary foods and beverages and pharmaceuticals. Hereinafter, as specific examples of xanthophyll and peptides, peptides derived from astaxanthin and red fish are described, respectively, but are not limited thereto.

  The mixing ratio of xanthophyll and peptide in the composition for improving eye accommodation function according to the present invention can be appropriately selected depending on the reactive oxygen species to be erased and the hydrophilicity and lipophilicity of the antioxidant, each of which is 1 in terms of free form. : It can mix | blend in the ratio of 0.1-1000, Preferably it is 1: 1-100. The adjustment function improving composition of the present invention can be blended in the range of 0.001 to 99.9% by weight, preferably 0.01 to 90% by weight, based on the total amount of blending target.

  The amount of astaxanthin used in the pharmaceutical and food and drink of the composition for improving eye accommodation function according to the present invention is an astaxanthin free form equivalent amount, 0.01 to 100 mg, preferably 0.1 to 20 mg per day in adults. The dose is taken orally or parenterally. The dosage varies depending on the age, weight, symptom level, and dosage form of the patient to be administered. The amount of astaxanthin in the pharmaceutical product of the present invention can be contained in an amount of 0.01 to 99% by weight, preferably 0.1 to 90% by weight.

  The amount of the peptide used in the pharmaceutical and food and drink of the composition for improving eye accommodation function according to the present invention is 0.1 to 1000 mg per day for an adult, preferably 1 to 100 mg, orally or parenterally. To do. The dosage varies depending on the age, weight, sex, degree of symptoms, and dosage form of the patient to be administered. The amount of the peptide in the pharmaceutical product of the present invention can be contained in an amount of 0.01 to 99% by weight, preferably 0.1 to 90% by weight.

  The dosage (ingestion amount) that can be immediately experienced in the regulatory function improving composition of the present invention is an amount that is difficult to ingest in the form of a normal food, and astaxanthin is 6 mg or more per day per adult human. The peptide is 500 mg or more. Below this, it is more effective for long-term use. These may be divided into meals or the like for the daily intake.

  The composition for improving eye accommodation function of the present invention has an effect for improving and preventing eye strain, which is said to be caused by deterioration of eye accommodation function. Particularly effective for neck / shoulder stiffness, low back pain, joint pain, and coldness caused by eye strain. The medicine, food and drink, and feed containing the composition of the present invention can have these effects. In the effects of the present invention, the improvement effect includes not only the improvement / treatment of symptoms that have developed, but also the prevention by taking in advance in an environment or constitution that is likely to develop.

  In order to assist the eye regulating function effect of the present invention, a substance having an assisting effect can be added. For example, vitamins A; carotenoids (excluding xanthophyll); vitamins B; vitamins C; vitamins D, vitamins E; tocotrienols; glutathione and derivatives thereof and salts thereof; catechins, anthocyanins, tannins, rutins, Polyphenols such as isoflavone, chlorogenic acid, ellagic acid, curcumin, and coumarin; linoleic acid, α- or γ-linolenic acid, arachidonic acid, eicosapentaenoic acid, succinic acid, docosahexaenoic acid and their derivatives, and salts thereof; collagen, elastin , Fibronectin, keratin proteins and their derivatives and hydrolysates; α-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid, salicylic acid and their derivatives and their salts; White, spleen, placenta, chicken crown, royal jelly, yeast, lactic acid bacteria, bifidobacteria, ganoderma, carrots, embellished, rosemary, oats, garlic, hinokitiol, cephalanthin, aloe, salvia, arnica, chamomile, birch, hypericum, eucalyptus, mukoji , Sempukuka, Caquette, Sunpens, Sakuhakuhi, Toki, Ibukitorano, Clara, Hawthorn, Shirayuri, Hops, Neubara, Yokuinin, Dokudami, Seaweed, Natto, Lemongrass, Hibiscus, and their extracts; adenosine triphosphate , Adenosine diphosphate, adenosine monophosphate and other adenylic acid derivatives; iron, vanadium, molybdenum, manganese, copper, potassium, magnesium, calcium, zinc, selenium, iodine and other minerals; mannitol Monosaccharides such as xylitol and glucosamine; polysaccharides such as hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, glycogen, chitin and chitosan; nucleic acids such as deoxyribonucleic acid and ribonucleic acid; other glycyrrhizic acid, One or more can be selected from the group consisting of guanine, mucin, ubiquinone, α-lipoic acid, octacosanol, allicin, alliin, and the like, and mixtures thereof. These components are generally blended in an amount of 0.01 to 90% by weight, preferably 0.1 to 50% by weight, based on the total amount of the pharmaceutical, and can be used in combination of one or more.

  The pharmaceutical agent containing the composition for improving the function of regulating eye according to the present invention can be administered orally. Oral dosage forms are administered in solid dosage forms such as tablets, buccal disintegrating tablets, capsules, granules, fine granules, and liquid dosage forms such as syrups and suspensions. Pharmaceutical products include quasi-drugs.

  The pharmaceutical agent containing the composition for improving ocular regulation function of the present invention may contain appropriate amounts of various additives used for the production of general preparations. Examples of such additives include excipients, binders, acidulants, foaming agents, artificial sweeteners, fragrances, lubricants, colorants, stabilizers, pH adjusters, and surfactants. Examples of excipients include corn starch, potato starch, wheat starch, rice starch, partially pregelatinized starch, pregelatinized starch, and starches such as porous starch, sugars such as lactose, sucrose, and glucose, mannitol, xylitol, Sugar alcohols such as erythritol, sorbitol, maltitol, magnesium aluminate metasilicate (product name "Neusilin" manufactured by Fuji Chemical Industry Co., Ltd.), hydrotalcite, anhydrous calcium phosphate [product name "Fujicalin", Fuji Chemical Industry Co., Ltd. )], Inorganic compounds such as precipitated calcium carbonate, calcium silicate, and light anhydrous silicic acid. Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gum arabic powder, gelatin, and pullulan. Examples of the disintegrant include starch, agar, carmellose calcium, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, crystalline cellulose, and F-MELT (trademark, manufactured by Fuji Chemical Industry Co., Ltd.). Examples of sour agents include citric acid, tartaric acid, malic acid, ascorbic acid and the like. Examples of the foaming agent include sodium bicarbonate and sodium carbonate. Examples of the sweetener include saccharin sodium, dipotassium glycyrrhizin, aspartame, stevia and thaumatin. Examples of the fragrances include lemon oil, orange oil, menthol and the like. Examples of the lubricant include magnesium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid, and sodium stearyl fumarate. Examples of the colorant include edible pigments such as edible yellow No. 5, edible red No. 2, and edible blue No. 2, edible lake pigments, and iron sesquioxide. Examples of the stabilizer include sodium edetate, tocopherol, cyclodextrin and the like. Examples of the pH adjuster include citrate, phosphate, carbonate, tartrate, fumarate, acetate, amino acid salt and the like. Examples of the surfactant include polysorbate 80, methyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyoxyethylene sorbitan monolaurate, gum arabic, and powdered tragacanth. In order to improve the absorption and formulation of astaxanthin and peptides, it can be in a powder state.

  The composition of this invention can be mix | blended and used for food-drinks and feed, and can acquire the effect similar to a pharmaceutical.

  As foods and beverages, supplements, functional health foods, and special-purpose foods are preferred because they can be used as supplements, functional health foods, special-purpose foods, and general foods, and the ease of intake and intake are easy to determine. Can be ingested in the same form, tablets, fast-disintegrating buccal tablets, solid dosage forms such as capsules, granules, fine granules, and liquid dosage forms such as syrups and suspensions. In addition to the ingredients used in the above pharmaceutical preparations, those that can be used in foods can be selected. In addition, milk protein, soy protein, egg albumin protein, etc., or egg white oligopeptide, soy hydrolyzate that is a degradation product thereof, A mixture of amino acids alone can also be used in combination. In addition, when provided in the form of a drink, nutritional additives such as amino acids, vitamins and minerals, sweeteners, spices, flavors and pigments may be added to improve the nutritional balance and flavor during intake. Good. The form of the food or drink of the present invention is not limited to these.

  In the present invention, foods and beverages permitted to improve or prevent symptoms are foods having medicinal effects that are permitted or designated by the government or public bodies, such as foods with nutritional functions and foods for specified health use. Such as health functional foods, special purpose foods, etc. Although names and rules vary depending on circumstances, times, and systems in each country, those that are essentially the same are included in the present invention.

  Examples of forms of general foods, that is, foods and drinks include margarine, butter, butter sauce, cheese, fresh cream, shortening, lard, ice cream, yogurt, dairy products, sauce meat products, fish products, pickles, french fries, potato chips , Snacks, kakimochi, popcorn, sprinkles, chewing gum, chocolate, pudding, jelly, gummy candy, candy, drop, caramel, bread, castella, cake, donuts, biscuits, cookies, crackers, macaroni, pasta, ramen, buckwheat, udon , Salad oil, instant soup, dressing, eggs, mayonnaise, miso, etc. or carbonated or non-carbonated beverages such as fruit juices, soft drinks, sports drinks, non-alcoholic beverages such as tea, coffee, cocoa It can be the addition example of liqueur, to common foods such as alcoholic beverages, such as medicinal liquor.

  In food and drink, astaxanthin and peptides are blended together with raw materials for general foods, and are manufactured by processing according to conventional methods. The amount of astaxanthin and peptide varies depending on the form of the food and is not particularly limited. In general, the amount of astaxanthin and peptide used can be appropriately selected by those skilled in the art according to the type of food and drink, and the amount described above is blended. can do.

  Even when the regulatory function improving composition of the present invention is blended in a feed, it is possible to obtain the same effects as pharmaceuticals and foods and drinks, for example, rats, rabbits, monkeys, dogs, cats, pigs, cows, sheep, horses, Can be administered to lizards, frogs, crocodiles, fish.

  The feed of the present invention is in the form of a solid preparation, solid, pellet, granule, biscuit, kneaded, etc., and dry food, semi-dry food (for example, feed having a water content of about 10 to 50% by weight), or wet such as canned food It is not particularly limited to food (for example, feed having a water content of about 50 to 80% by weight). Astaxanthin and peptide can be added to and mixed with feed materials or mixed with an aqueous solution of astaxanthin and peptide by a suitable process in the conventional feed production process. Also, like human dietary supplements, it should be manufactured with solid preparations such as tablets, sublingual tablets, pills, powders, powders, fine granules, granules, capsules and soft capsules that are easy to ingest. Can do.

  There are no particular restrictions on the ingredients that can be used as long as they can be used as feed, but feed ingredients that are commonly used depending on the type of feed, such as fish meal, fish, seafood, fishmeal, and livestock meat. Animal raw materials such as meat powder, meat and bone meal, blood meal, feather meal, cocoon oil cake, skim milk powder, animal fats (beef oil, pork oil, bone oil, etc.), eggs, milk, etc .; beer yeast, torula yeast, etc. Microorganisms; corn, milo, wheat, barley, rye, oats, wheat flour, brown rice, millet, soybeans, quinako, cassava and other grains; pregelatinized starch, starches such as starch; Oil pods such as peanut oil coconut, palm oil cocoon, sunflower oil cocoon, linseed oil cocoon, sesame oil cocoon, safflower oil cocoon, palm kernel oil cocoon, kapok oil cocoon; rice bran, barley bran, bran Nuka's; Gurung feed, gluten meal, starch cake, honey, soy sauce cake, beer cake, beet pulp, bagasse, tofu cake, malt root, citrus peel, tangerine juice cake, etc .; alfalfa meal, timothy hay, Fibrin such as koji; excipients, binders, disintegrants, saccharides such as salt and sugar, vitamins, amino acids, minerals and other components can be used alone or in combination.

  As a raw material which can be blended in a solid preparation, in addition to the above-mentioned raw materials, for example, it can be produced by uniformly mixing with a carrier generally used in the human food field. Specifically, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, rapeseed oil, olive oil and soybean oil, and flavors such as strawberry flavor and peppermint Can be manufactured using. Also in the form of powders, pills, capsules, soft capsules, tablets, excipients such as lactose, glycolose, sucrose, lactose, mannitol, corn starch, silicon dioxide, disintegrants such as starch and sodium alginate, magnesium stearate Lubricants such as talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose, gelatin and casein, glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, saponins, lecithin and other emulsifiers, guar gum, alginic acid, carrageenan, agar , Pectin, gum arabic, and thickeners such as crystalline cellulose, and plasticizers such as glycerin. As the tablet form, tablets and capsules are preferable because they are easy to ingest.

The present invention will be described in detail in the following examples and formulation examples, but the present invention is not limited thereto.

[Example 1] Astaxanthin improves eye accommodation ability (test method) Subjects who satisfy the following selection criteria were used as subjects.
(1) A person with a subjective symptom of eye fatigue or a person engaged in VDT work. (2) Corrected visual acuity 1.0 or more with both eyes. (3) Age 33-45. (4) People who are not taking medicines and health foods at all times. (5) A person who can observe the matters to be observed and receive medical examinations stipulated in the test method. A person who is judged unsuitable for study participation by the investigator for reasons such as illness.

(Sample) Soft capsules 100 mg of soft capsule shell (75% by weight of gelatin, 25% by weight of glycerin) was kneaded with 200 mg of capsule contents consisting of the following components and filled to obtain 300 mg of soft capsules in a conventional manner. In addition, a compounding quantity is weight%. Astaxanthin is an extract produced from Haematococcus alga extract oil containing 5% by weight of astaxanthin in terms of free form. As the bonito extract, a commercially available bonito extract (manufactured by Riken Vitamin) was used.

[Table 1] Soft capsule contents

I. The pre-intake test was conducted in a double-blind manner so that the tester and subjects did not know the food content. That is, the person in charge of the test can clearly detect a dysregulation such as VDT syndrome (D'ACOMO) [D'ACOMO] manufactured by Wack. After completing the adjustment test, the subjects were stratified according to gender and test results, and a list was created and passed to the controller. Based on this list, the controller divided the subjects into the test food group and the control food group and created an allocation table. Furthermore, according to the allocation table, a label indicating the name of each subject was attached to the test meal or the control meal. The allocation table was sealed by the controller. The assignment table was forbidden until the controller completed the analysis of the test results.

II. Ingestion Capsules were prepared according to the above formulation, and 12 males and 12 females in each group were taken as a panel and were ingested daily for 2 weeks and 4 weeks immediately after dinner.

III. After ingestion, subjects underwent D'ACOMO testing for regulation.
The results are shown in Table 1. The table shows the human eye accommodation power of the test food group and the human eye accommodation power of the control group.
In addition, the value of the adjustment power (degree diopter) in the table is expressed as an average value ± standard deviation, and the significant difference was set to p <0.05. A is before intake vs. after intake, b is preparation 2 vs. preparation 4 after intake, and c is a significant difference in t-test of preparation 3 vs. preparation 4 after intake.

[Table 2] Results of accommodation test

  From the results of Table 2 above, when comparing the human eye accommodation before start of astaxanthin intake and after continuous intake for 4 weeks, the test meal group (formulations 2, 3 and 4) showed an improvement with a statistically significant difference. On the other hand, such a difference was not recognized in the control group (formulation 1). Further, when Formulation 4 and Formulation 2 or Formulation 3 were compared with each other after ingestion, Formulation 4 was significantly improved over Formulations 2 and 3. From this, it can be seen that the combined use of astaxanthin and bonito extract improves the eye's ability to adjust compared to when used alone.

Example 2 Subjective Symptoms of Eye Fatigue For each group of Example 1, with regard to the items “eye is tired”, “eye is blurred”, “shoulder / waist is stiff”, and “head hurts” A questionnaire was conducted on the subjects. The degree of symptom was divided into four levels of “none”, “a little”, “medium”, and “very”, and the number of subjects who showed symptoms at each stage is shown in Table 3-6.

[Table 3] Subjective symptoms: eyes get tired

[Table 4] Subjective symptoms: blurred vision

[Table 5] Subjective symptoms: stiff shoulders and lower back

  From the results of Table 3-6 above, improvement in subjective symptoms was observed for both Formulations 2, 3 and 4 compared to Formulation 1. Furthermore, it was confirmed that the preparation 4 was improved more than the preparations 2 and 3. As a result, astaxanthin and bonito extract are effective when used alone, but when both are used together, the effect is more synergistically recognized.

[Production Example 1] Tablet According to a conventional method, the following components were uniformly mixed and tableted at the following composition ratio (% by weight) to give a tablet of 300 mg per tablet.
Asteryl powder 66.7 parts by weight Hondashi 33.3 parts by weight Lactose 5 parts by weight Potato starch 12 parts by weight Polyvinyl alcohol 2 parts by weight Magnesium stearate 1 part by weight Asteryl powder [manufactured by Fuji Chemical Industry Co., Ltd.] is converted to free form The powder produced from Haematococcus alga extract oil containing 1% by weight of astaxanthin, and Hondashi [Ajinomoto Co., Ltd.] is a powder containing bonito extract%.

[Production Example 2] Intraoral rapidly disintegrating tablet The following ingredients were uniformly mixed and tableted in the following composition ratio (% by weight) according to a conventional method to obtain a tablet of 300 mg per tablet.
Asterel powder 25 parts by weight Boulder 13 parts by weight F-MELT 30 parts by weight Rice starch 10 parts by weight Magnesium stearate 1 part by weight F-MELT (manufactured by Fuji Chemical Industry Co., Ltd.) An excipient that can be manufactured.

[Formulation Example 3] Powdered juice According to a conventional method, an appropriate amount of water was added to the following ingredients, and the mixture was uniformly mixed at the following composition ratio (% by weight) to prepare granules.
Asterel powder 66.7 parts by weight Hondashi 33.3 parts by weight Potato starch 12 parts by weight Gelatin 2 parts by weight

[Formulation example 4] Drink agent The following ingredients were blended, and water was added to 10 L according to a conventional method to prepare a drink agent.
Water-soluble astaxanthin solution 50g
4g
Liquid sugar 1000g
DL-sodium tartrate 1g
Citric acid 10g
Vitamin C 10g
Vitamin E 20g
25 g of cyclodextrin
Potassium chloride 2g
Magnesium sulfate 1g
A water-soluble astaxanthin solution [manufactured by Fuji Chemical Industry Co., Ltd.] is obtained by making an aqueous solution of Haematococcus alga extract oil containing 0.5% by weight of astaxanthin in terms of free form.

  ADVANTAGE OF THE INVENTION By this invention, the food / beverage which has the improvement effect of the eye accommodation disorder | damage | failure which consists of an xanthophyll and a peptide, and the eye accommodation disorder | damage | failure consisting of an astaxanthin and a peptide could be provided. A composition consisting of xanthophyll and peptide improves the eye's ability to adjust more effectively, so that the ability to adjust the eye is impaired, i.e., eye strain, aging changes, and the ability to adjust decreases. Prevention of presbyopia, VDT, or tired eyes when engaged in work that frequently uses the eyes, and disorders such as dysregulation of morbidity, dysregulation, dysregulation, paralysis, accommodation tension, and convulsions And / or useful as a therapeutic agent.

Claims (11)

An ophthalmic regulatory dysfunction improving composition comprising xanthophyll and a peptide. The composition for improving an eye accommodation function according to claim 1, wherein xanthophyll is 0.01 to 100 mg and peptide is 0.1 to 1000 mg. Xanthophyll is astaxanthin, The composition for improving ocular regulatory dysfunction according to any one of claims 1 to 2. The composition for improving an eye regulation dysfunction according to any one of claims 1 to 3, wherein the peptide is a peptide contained in an extract derived from red fish. The red fish is at least one member of the group consisting of horse mackerel, sardine, anchovy, bonito, amberjack, mackerel, sawara, saury, striped mackerel, herring, yellowtail, tuna and mud horse mackerel. A composition for improving the impairment of eye accommodation. A composition for improving an eye accommodation function, comprising one or more of the following groups in the composition according to any one of claims 1 to 5;
Carotenoids (excluding xanthophyll); Vitamin B; Vitamin C; Vitamin D, Vitamin E; Tocotrienols; Glutathione and their derivatives and their salts; catechin, anthocyanin, tannin, rutin, isoflavone, Polyphenols such as chlorogenic acid, ellagic acid, curcumin, coumarin; linoleic acid, α- or γ-linolenic acid, arachidonic acid, eicosapentaenoic acid, sardine acid, docosahexaenoic acid and their derivatives and salts thereof; collagen, elastin, fibronectin , Proteins selected from keratin and derivatives thereof and hydrolysates; α-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid, salicylic acid and their derivatives and salts thereof; serum deproteinization, spleen , Placenta, chicken crown, royal jelly, yeast, lactic acid bacteria, bifidobacteria, ganoderma, carrots, assembly, rosemary, oats, garlic, hinokithiol, cephalanthin, aloe, salvia, arnica, chamomile, birch, hypericum, eucalyptus, mugwort, sempukuka, Natural products such as keiketou, sunpens, sakuhakuhi, touki, ibukitorano, clara, hawthorn, shirayuri, hops, noibala, yokuinin, dokudami, seaweed, natto, lemongrass, hibiscus and their extracts; adenosine triphosphate, adenosine Adenylic acid derivatives such as phosphoric acid and adenosine monophosphate; minerals such as iron, vanadium, molybdenum, manganese, copper, potassium, magnesium, calcium, zinc, selenium, iodine; mannitol, xylyl Monosaccharides such as hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, glycogen, chitin, chitosan; nucleic acids such as deoxyribonucleic acid and ribonucleic acid; other glycyrrhizic acid , Guanine, mucin, ubiquinone, α-lipoic acid, octacosanol, allicin, alliin. The composition according to any one of claims 1 to 6, which improves eyestrain, muscle fatigue, and fatigue by improving eye accommodation dysfunction. A pharmaceutical comprising the composition for improving impairment of eye regulation according to any one of claims 1 to 6. A food or drink comprising the composition for improving impairment of eye regulation according to any one of claims 1 to 6. The food or drink according to claim 9, wherein the effect of improving eye accommodation dysfunction and the improvement of symptoms by the improvement are permitted. A method for using xanthophyll and a peptide for producing a composition for improving ocular regulatory dysfunction.